Clinical Trial

Integrative Diagnosis for SCD and Other RADs

Study acronym: INTEGRA
Recruiting
View on ClinicalTrials.gov →
Summary
INTEGRA aims at enabling personalized medicine for RHADs patients by the establishment of an integrative diagnostic approach based on deep phenotypic and genetic characterization through combining new generation methodologies.
Trial Details
NCT Number NCT07206095
Lead Sponsor Hospital Universitari Vall d'Hebron Research Institute
Collaborators: Hospital Clinic of Barcelona, Institute for Bioengineering of Catalonia, Hospital Arnau de Vilanova, Lleida (Spain)
Conditions Sickle Cell Disease, Thalassaemia, Congenital Dyserythropoietic Anemia (CDA), Enzyme Disorder; Anemia, Spherocytosis, Hereditary, Stomatocytosis, Hemoglobin Disorder, Anemia Due to Membrane Defect +1 more
Enrollment 200 participants
Start Date 2020-11-13
Primary Completion 2025-05-25 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2025-10-03